MACROGENICS INC 8K

MacroGenics reported Q2 2026 results highlighted by the sale of its manufacturing operations and workforce restructuring, strengthened cash position and runway through 2028, and continued advancement of its oncology pipeline and partnership milestones.

On August 13, 2026, MacroGenics, Inc. reported its second quarter 2026 financial results and significant corporate developments, including the completed July 2026 sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals/Bora Biologics for a base purchase price of $122.5 million (with $119.6 million cash received at closing), a concurrent restructuring that will reduce its workforce to approximately 140 employees and transition the company to a fully outsourced manufacturing model, and multiple business development and pipeline milestones such as a $24.5 million regulatory milestone from Sanofi related to TZIELD®, a $10 million option exercise payment from Gilead under a bispecific collaboration, pro forma liquidity of $327 million supporting cash runway guidance through 2028, and continued advancement of key oncology programs including MGC026, MGC028, MGC030, lorigerlimab, and new preclinical candidate MGD032.

Filing Facts

CIK

1125345

Ticker

-

Form

8K

Source Type

sec

Accession

0001125345-26-000054

Alert Tier

7